Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 131

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 131
---
 avoiding or decreasing an obligation to pay money to the federal government. The False Claims Act has been used to assert liability on the basis of kickbacks and other improper referrals,    
 improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, and improper promotion of off-label uses (i.e., uses not expressly approved by the FDA in a drug’s label);                                               |

| • |     | the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and                                                                                                                                       
 medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to             
 physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), teaching hospitals and, beginning in 2022, certain other healthcare professionals, as well as ownership and investment interests held by the physicians 
 described above and their immediate family members;                                                                                                                                                                                                     |

| • |     | federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and 
 activities that potentially harm consumers;                                                                |

| • |     | the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical 
 devices;                                                                                                       |

| • |     | federal government price reporting laws, which require drug manufacturers to calculate and report complex pricing 
 metrics to government agencies, including CMS and Department of Veterans Affairs                                  |

80

| (“VA”), referred to as Government Program Statutory Price Reporting, where such reported prices are used in the calculation of reimbursement and/or discounts on marketed products paid                                                                 
 by government healthcare programs. Participation in these programs and compliance with the applicable requirements may result in potentially significant discounts on products subject to reimbursement under federal healthcare programs and increased 
 infrastructure costs, and may potentially limit a drug manufacturer’s ability to offer certain marketplace discounts. Additionally, if it is determined by the government, which could include a government agency such as CMS, Health Resources and    
 Services Administration (“HRSA”), the VA, or by the Office of Inspector General or Department of Justice, that the Statutory Price Reporting was incorrect, causing the government to essentially pay more than they should through the                 
 reimbursement and/or discount, the manufacturer may be subject to significant False Claims Act investigations, civil monetary penalties and/or additional fines;                                                                                        |

| • |     | the Prescription Drug Marketing Act, which restricts the manner in which manufacturers may disseminate                                                             
 complimentary drug samples